Tiragolumab
Tiragolumab is an antibody pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
67 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 10 | 4 | — | — | 14 |
| Neoplasms | D009369 | — | C80 | 1 | 7 | 1 | — | — | 8 |
| Lung neoplasms | D008175 | — | C34.90 | — | 4 | 2 | — | — | 6 |
| Small cell lung carcinoma | D055752 | — | — | — | 1 | 2 | — | — | 3 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | 2 | 1 | — | — | 3 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 2 | 1 | — | — | 3 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | 2 | 1 | — | — | 3 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | 1 | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | — | 6 | — | — | — | 6 |
| Squamous cell carcinoma | D002294 | — | — | — | 6 | — | — | — | 6 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 4 | — | — | — | 4 |
| Squamous cell neoplasms | D018307 | — | — | — | 4 | — | — | — | 4 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 2 | — | — | — | 3 |
| Head and neck neoplasms | D006258 | — | — | 1 | 2 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | 1 | 2 | — | — | — | 3 |
| Melanoma | D008545 | — | — | 1 | 3 | — | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
| Urinary bladder neoplasms | D001749 | — | C67 | 2 | 1 | — | — | — | 2 |
Show 26 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tiragolumab |
| INN | tiragolumab |
| Description | Tiragolumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >8JEQ:A|antibody heavy chain
EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGKTYYRFKWYSDYAVSVKGRITINPDTSKN
QFSLQLNSVTPEDTAVFYCTRESTTYDLLAGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH
>8JEQ:B|antibody light chain
DIVMTQSPDSLAVSLGERATINCKSSQTVLYSSNNKKYLAWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLT
ISSLQAEDVAVYYCQQYYSTPFTFGPGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL
QSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 8JEO, 8JEQ |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298050 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 6XG22YQM2Z (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 948 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
567 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use